Lilly and GlycoFi will initiate research on 10 protein optimization programs over the extendable two-year research term. The companies will integrate the GlycoFi technology platform into Lilly’s research
In this multicenter, randomized, double-blind, parallel group trial, the safety and efficacy of oxymorphone ER were compared with placebo in 142 opioid-experienced patients with moderate-to-severe chronic low back
Combined, the 20 countries covered by the agreement represent annual pharmaceutical sales of more than $13 billion and pain product sales of more than $1.2 billion. Labopharm has
Under the first phase of the contract, Human Genome Sciences will receive $1.8 million to supply ten grams of ABthrax to the US Department of Health and Human
The technology, known as UCOE (ubiquitous chromatin opening element), improves the yield, consistency and stability of protein production in cultured mammalian cells, allowing simpler and quicker generation of
LigoCyte’s intranasal anthrax vaccine is a dual-antigen vaccine that protects against both the anthrax toxin and the infectious disease process. The dry powder formulation offers the potential for
VivaGel has already been successfully tested in a number of studies including a phase I human safety trial. This new funding will accelerate the progress of VivaGel to
In a mouse model of human prostate cancer, PSMA ADC (prostate-specific membrane antigen antibody-drug conjugate) significantly prolonged overall survival up to nine-fold as compared to untreated animals. Remarkably,
The product is recombinant human Mannan-Binding Lectin (rhMBL), a protein therapeutic being developed for the prevention of severe infections in MBL-deficient individuals undergoing chemotherapy. Enzon receives exclusive worldwide
Nektar’s novel drug-device system uses a nebulizer and Nektar proprietary adapter technology, along with a unique formulation of liquid antibiotics, to target the lungs directly with preventative doses
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.